Evidence map›Paper›PMID 41051533›Full record

ArticleEuropean journal of clinical pharmacology2025

Influence of genetic variants of imatinib on pharmacokinetics and recurrence-free survival in postoperative patients with gastrointestinal stromal tumor.

Luning Sun, Mingqing Xu, Qiang Zhang, Yi Liu, Qiongye Huang, Jianghao Xu, Fengyuan Li, Hao Xu, Yongqing Wang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luning Sun *Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210009, China.
Mingqing Xu *Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210009, China.
Qiang ZhangDepartment of General Surgery, First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Jiangsu Province 210029, Nanjing, China.
Yi LiuResearch Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210009, China.
Qiongye HuangResearch Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210009, China.
Jianghao XuDepartment of General Surgery, First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Jiangsu Province 210029, Nanjing, China.
Fengyuan LiDepartment of General Surgery, First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Jiangsu Province 210029, Nanjing, China.
Hao XuDepartment of General Surgery, First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Jiangsu Province 210029, Nanjing, China. hxu@njmu.edu.cn.
Yongqing WangResearch Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210009, China. wyqjsph@163.com.

Funding

Jiangsu Pharmaceutical Association-Aosaikang Pharmaceutical Co.Ltd Hospital Pharmacy Research Key Project A202204the grants from National Natural Sciences Foundation of China 82274022the third session of the support programs for topnotch talents, Jiangsu Provincial People's Hospital, China YNRCQN025
6 · The paper itself

Abstract

purposeImatinib is the first-line therapy for gastrointestinal stromal tumor (GIST), significantly enhancing patient prognosis. However, its clinical efficacy and safety are highly dependent on plasma concentration, which exhibits considerable interindividual variability. The purpose of this study is to determine the optimal monitoring time for imatinib concentration in postoperative patients with GIST, analyze single nucleotide polymorphisms affecting plasma concentration, and investigate their correlation with efficacy and adverse drug reactions (ADRs), offering valuable insights for personalized therapy.

methodsThis study was conducted on 116 postoperative patients with GIST treated with imatinib in China between 2014 and 2018. Imatinib peak and trough concentrations (C

resultsThe C

conclusionsImatinib plasma concentration was stabilized by the third month in postoperative patients with GIST. Genetic polymorphisms in ABCG2, SLC22A1, and SLC22A5 (OCTN2) were associated with imatinib plasma concentration, while SLC22A5 (OCTN2) also influenced recurrence rates. These results provide a reference for personalized therapy and concentration monitoring.

Indexed as

Antineoplastic AgentsGastrointestinal NeoplasmsGastrointestinal Stromal TumorsImatinib MesylateAdultAgedCytochrome P-450 CYP3ADisease-Free SurvivalFemaleGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideYoung AdultAntineoplastic AgentsCYP3A5 protein, humanCytochrome P-450 CYP3AImatinib MesylateGastrointestinal stromal tumorGenetic polymorphismImatinibPeak concentrationPharmacokineticsPostoperativeRecurrence-free survivalTrough concentration

Identifiers

PMID41051533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.